Dragovich, Tomislav

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 1,222

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 277

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 197

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

Ramanathan, R. K., Abbruzzese, J., Dragovich, T., Kirkpatrick, L., Guillen, J. M., Baker, A. F., Pestano, L. A., Green, S., & Von Hoff, D. D. (2011) · Cancer Chemotherapy and Pharmacology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 122

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma

Baker, A. F., Dragovich, T., Tate, W. R., Ramanathan, R. K., Roe, D., Hsu, C.-H., Kirkpatrick, D. L., & Powis, G. (2006) · Journal of Laboratory and Clinical Medicine

Redox biology and oxidative stressGlutathione Transferases and Polymorphisms

Cited by 90

A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers

Baker, A. F., Adab, K. N., Raghunand, N., Chow, H. H. S., Stratton, S. P., Squire, S. W., Boice, M., Pestano, L. A., Kirkpatrick, D. L., & Dragovich, T. (2013) · Investigational New Drugs

Redox biology and oxidative stressGastric Cancer Management and Outcomes

Cited by 52